- 1 Title: Identification of an ANCA-Associated Vasculitis Cohort Using Deep Learning and
- 2 Electronic Health Records
- 3 **Running head**: Deep Learning in ANCA-Associated Vasculitis Identification
- 4 Authors: Liqin Wang, PhD<sup>1</sup>; John Novoa-Laurentiev, MS<sup>1</sup>; Claire Cook, MPH<sup>2</sup>; Shruthi
- 5 Srivatsan, BA<sup>2</sup>; Yining Hua, MS<sup>3</sup>; Jie Yang, PhD<sup>4</sup>; Eli Miloslavsky, MD<sup>5</sup>; Hyon K. Choi,
- 6 MD, DrPH<sup>2</sup>; Li Zhou, MD, PhD<sup>1</sup>, Zachary S. Wallace, MD, MSc<sup>2</sup>

## 7 Affiliations:

- <sup>1</sup>Division of General Internal Medicine and Primary Care, Department of Medicine,
- 9 Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts,
- 10 USA
- 11 (Iwang@bwh.harvard.edu, jlaurentiev@bwh.harvard.edu, Izhou@bwh.harvard.edu)
- <sup>2</sup> Rheumatology and Allergy Clinical Epidemiology Research Center and Division of
- 13 Rheumatology, Allergy, and Immunology, and Mongan Institute, Department of
- 14 Medicine, Massachusetts General Hospital, Boston, MA, USA
- 15 (ccook13@mgh.harvard.edu, ssrivatsan1@mgh.harvard.edu, hchoi@mgh.harvard.edu,
- 16 zswallace@mgh.harvard.edu)
- <sup>3</sup> Department of Epidemiology, Harvard T.H. Chan School of Public Health
- 18 (yining\_hua@hms.harvard.edu)
- <sup>4</sup> Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,
- 20 Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts,
- 21 USA (jyang66@bwh.harvard.edu)
- <sup>5</sup> Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital
- and Harvard Medical School, Boston, MA, USA (*emiloslavsky@mgh.harvard.edu*)

24	Funding support: Authors of this work are supported by the National Institutes of
25	Health [grant numbers K23AR073334, R03AR078938, L30AR070520, R03AR078938,
26	K99AG075190]. The funders had no role in the design and conduct of the study;
27	collection, management, analysis, and interpretation of the data; preparation, review, or
28	approval of the manuscript; and decision to submit the manuscript for publication.
29	Conflict of Interest: ZSW reports research support from Amgen, Bristol-Myers Squibb,
30	and Principia/Sanofi, consulting fees from Amgen, Viela Bio, Horizon, Zenas
31	Biopharma, PPD, and MedPace, and has served on advisory boards for Amgen,
32	Horizon, Novartis, Sanofi, Shinogi, and Visterra/Otsuka. All other authors report no
33	disclosures.
34	Corresponding Author:
35	Liqin Wang, Ph.D.
36	Division of General Internal Medicine and Primary Care
37	Brigham and Women's Hospital
38	399 Revolution Drive, AR01-13-E58
39	Somerville, MA 02145, USA
40	Tel: 857-282-4089   Fax: 857-282-5754   E-mail: <u>lwang@bwh.harvard.edu</u>
41	
42	Content:
43	Word count: Abstract 273; Manuscript 3899
44	Figures: 2
45	Tables: 4
46	References: 14

2

## 47 **ABSTRACT**

48 **Background**: ANCA-associated vasculitis (AAV) is a rare but serious disease.

49 Traditional case-identification methods using claims data can be time-intensive and may

- 50 miss important subgroups. We hypothesized that a deep learning model analyzing
- 51 electronic health records (EHR) can more accurately identify AAV cases.
- 52 **Methods**: We examined the Mass General Brigham (MGB) repository of clinical
- documentation from 12/1/1979 to 5/11/2021, using expert-curated keywords and ICD
- codes to identify a large cohort of potential AAV cases. Three labeled datasets (I, II, III)
- were created, each containing note sections. We trained and evaluated a range of

56 machine learning and deep learning algorithms for note-level classification, using

57 metrics like positive predictive value (PPV), sensitivity, F-score, area under the receiver

<sup>58</sup> operating characteristic curve (AUROC), and area under the precision and recall curve

59 (AUPRC). The deep learning model was further evaluated for its ability to classify AAV

cases at the patient-level, compared with rule-based algorithms in 2,000 randomly

61 chosen samples.

62 **Results**: Datasets I, II, and III comprised 6,000, 3,008, and 7,500 note sections,

respectively. Deep learning achieved the highest AUROC in all three datasets, with

scores of 0.983, 0.991, and 0.991. The deep learning approach also had among the

highest PPVs across the three datasets (0.941, 0.954, and 0.800, respectively). In a test

cohort of 2,000 cases, the deep learning model achieved a PPV of 0.262 and an

- 67 estimated sensitivity of 0.975. Compared to the best rule-based algorithm, the deep
- learning model identified six additional AAV cases, representing 13% of the total.

- 69 **Conclusion**: The deep learning model effectively classifies clinical note sections for
- 70 AAV diagnosis. Its application to EHR notes can potentially uncover additional cases
- 71 missed by traditional rule-based methods.
- 72 Keywords: ANCA-associated vasculitis; Case Identification; Deep Learning; Machine
- 73 learning; Electronic Health Records; Clinical Notes
- 74

# 75 SIGNIFICANCE AND INNOVATIONS:

- Traditional approaches to identifying AAV cases for research have relied on
- registries assembled through clinical care and/or on billing codes which may miss
- 78 important subgroups.
- Unstructured data entered as free text by clinicians document a patient's
- 80 diagnosis, symptoms, manifestations, and other features of their condition which
- 81 may be useful for identifying AAV cases
- We found that a deep learning approach can classify notes as being indicative of
- AAV and, when applied at the case level, identifies more cases with AAV than
- rule-based algorithms.

#### INTRODUCTION 85

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a rare 86 immune-mediated inflammatory disease associated with substantial morbidity, mortality, 87 and resource utilization.<sup>1, 2</sup> The disease presents in patients with heterogeneous 88 manifestations (e.g., glomerulonephritis, sinusitis, skin rash, pulmonary nodules) to 89 90 clinicians from a variety of specialties (e.g., rheumatology, nephrology, otolaryngology, intensive care) across the care spectrum within healthcare systems (e.g., community 91 hospital, tertiary care hospital, outpatient clinic, emergency departments). AAV case 92 93 identification in electronic health records (EHR), an increasingly important source for epidemiologic research, is limited by a lack of well-performing methods to identify 94 95 cases.

96

To enable outcomes and comparative effectiveness studies using large, phenotypically 97 diverse cohorts from big data, a novel AAV case-finding algorithm is needed. Previous 98 studies have demonstrated that rule-based algorithms relying on ICD-9 codes for AAV 99 case identification have poor performance, partly because there is no specific ICD-9 100 code for microscopic polyangiitis (MPA), a subtype of AAV, and many MPA patients 101 may be miscoded using less specific ICD-9 codes. Additionally, the previously 102 developed algorithms, which require a positive ANCA test result or the use of multiple 103 104 ICD codes, may exclude important and informative subgroups of patients, including ANCA-negative granulomatosis with polyangiitis (GPA) and those who die soon after 105 diagnosis from severe disease or complications. The performance of algorithms that 106 107 incorporate ICD-10 codes has not been previously assessed.

108

109 In addition to billing code data and test results, EHR data include unstructured data entered as free text by clinicians documenting a patient's diagnosis, symptoms, 110 manifestations, and other features of their condition. We have previously demonstrated 111 that these notes can be leveraged to characterize the temporal course of AAV.<sup>3</sup> Other 112 studies have suggested that unstructured data can enhance the performance of case-113 finding algorithms for other conditions, but this remains underexplored for prototypic 114 rare conditions like AAV.<sup>4-7</sup> Here, we hypothesized that machine learning methods could 115 be utilized to develop case-finding algorithms that accurately identify AAV patients and 116 that these algorithms would outperform or produce more phenotypically diverse cohorts 117 than rule-based algorithms. 118

119

#### 120 MATERIALS AND METHODS

#### 121 **Overview**

This study was conducted at Mass General Brigham (MGB), a large, integrated 122 123 healthcare delivery system in the Greater Boston area, Massachusetts. We used data from MGB's research patient data registry (RPDR). The study was approved by the 124 MGB's Institutional Review Board (IRB number: 2016P000633). Figure 1 illustrates the 125 126 overall process for the development of the AAV case-finding algorithms. We first created a screening cohort of potential AAV cases. We then created three labeled 127 datasets from three cohorts for the development and evaluation of multiple machine 128 learning models for AAV case identification from unstructured clinical notes. The deep 129 learning model was further deployed to identify AAV patients from a random sub-cohort 130

of patients. The performance of this model was compared against rule-basedapproaches.

133

#### 134 Study Cohorts

The screening cohort was constructed using all data from RPDR, spanning its inception 135 on December 1, 1979, through May 11, 2021. We identified potential AAV patients 136 based on the presence of at least one AAV-related ICD code in a diagnosis field or the 137 use of a keyword in clinical notes. **Supplemental Table 1** lists keywords selected by the 138 subject-matter experts (EM and ZSW). To develop and evaluate the performance of 139 machine learning algorithms for AAV case identification, we used three distinct cohorts. 140 Cohort A comprised 700 patients with confirmed AAV, as they were previously identified 141 as part of the MGB AAV Cohort between January 01, 2002, and December 31, 2019.<sup>8</sup> 142 Cohorts B and C were random samples of 1000 patients each from the screening 143 cohort. 144

145

#### 146 **Processing of Clinical Notes**

For each study cohort, we extracted all available clinical notes included in RPDR database any time before July 23, 2021. These notes encompassed visit notes, progress notes, ambulatory notes, history and physical exam notes, and discharge summaries. Clinical notes contain rich information, such as clinical manifestations, physical exams, and differential diagnoses, which are useful to determine whether patient does or does not have AAV. However, due to the voluminous number of notes that each patient accumulates over years of interaction with a healthcare system, the

154	model could miss true signals when handling large datasets. Thus, we processed each
155	note into smaller sections and then applied the models being tested to evaluate their
156	ability to predict whether or not the text refers to a diagnosis of AAV. To split the notes
157	into sections, we used Medical Text Extraction, Reasoning, and Mapping System
158	(MTERMS), an in-house developed natural language processing (NLP) system.9
159	
160	Definition of AAV Classification Task
161	We approached the identification of AAV as a classification task, training models for
162	binary classification of note sections as pertaining to AAV. Throughout model
163	development, we assessed and compared the effectiveness of these models at the note
164	section level. In practical applications for patient identification, a patient was classified
165	as having AAV if any of their note sections were predicted positive, suggesting an AAV
166	diagnosis. Conversely, a patient was deemed not to have AAV if all their note sections
167	were predicted negative.
168	
169	Development of Labeled Datasets
170	We developed three labeled datasets to train, test, and compare multiple machine
171	learning algorithms. Datasets I and II contained note sections that were derived from the
172	same population, i.e., patients with validated AAV (Cohort A) as well as patients with
173	possible AAV (Cohort B). To increase the positive case density in Dataset I, we applied
174	a list of expert-curated keywords to filter for sections that likely contain references to a
175	diagnosis of AAV or the presence of AAV manifestations (Supplemental Table 2). To
176	assess the generalizability of the trained models to note sections, regardless of keyword

presence, we established Dataset II by randomly selecting note sections from those not included in Dataset I. Specifically, Dataset I included 5,000 sections from cohort A and 1,000 sections from cohort B, all mentioning specific keywords. Dataset II contains 2,000 sections from cohort A and 1,000 sections from cohort B, selected randomly without considering keyword references. Dataset III consists of 7,500 note sections randomly selected from Cohort C, a subset of the screening cohort, to evaluate model performance in identifying potential AAV patients.

184

### 185 **Dataset Annotation**

Two subject matter experts (ZSW and CC) labeled each selected section from clinical 186 notes for whether it indicated that the diagnosis of AAV was present. Cases were 187 188 classified as AAV based on a prior algorithm for identifying AAV in epidemiologic studies.<sup>10</sup> In cases where there was limited data available to apply this algorithm, we 189 classified a case as AAV if the treating provider and both chart reviewers agreed on the 190 191 classification of the case as AAV. Patients with eosinophilic granulomatosis with polyangiitis (EGPA) were classified as negative. Although EGPA is a specific type of 192 AAV, it presents a different etiology, pathology, and clinical features compared to other 193 AAV types, such as GPA and MPA.<sup>11</sup> The annotators first individually labeled 100 194 sections and any conflicts were resolved by consensus. Then in the second dataset of 195 196 100 sections, two annotators achieved near-perfect agreement with a Cohen's kappa of 0.897. The remaining note sections were each annotated by one of the annotators. Any 197 cases for which labeling was uncertain were resolved through consensus by ZSW and 198 CC. 199

200

## 201 Model Development

We first implemented four basic statistical machine learning algorithms, including logistic regression, random forest, support vector machine (SVM), and XGBoost.<sup>12</sup> The note sections were processed into n-grams (where n=1). Each section was converted into term frequency-inverse document frequency vectors based on n-grams. The algorithms were trained and tested with 5-fold cross validation using the Dataset I.

207

We also implemented a hierarchical attention-based deep neural network, which 208 209 includes a convolutional neural network for handling word variations (e.g., plural, misspelling), a recurrent neural network for handling context (e.g., negation), and 210 211 attention layers for interpreting predictions. We chose this algorithm as it was previously proved to be effective in allergic reaction detection from hospital safety reports<sup>5</sup> and 212 cognitive decline detection from clinical notes.<sup>4</sup> When implementing this deep learning 213 214 algorithm, each note section was treated as a sequence of tokens, and individual words were represented by word embedding. We used pre-trained word embedding, named 215 BioWordVec, which is an open set of biomedical word vectors that integrated 216 biomedical text with Medical Subject Headings (MeSH) using the fastText model.<sup>13</sup> 217 218

Additionally, we implemented BioClinicalBERT, a domain-specific Bidirectional Encoder Representation from Transformers (BERT) model,<sup>14</sup> on the labeled dataset. BERT is one of the most widely-used deep contextualized language models, achieving state-ofthe-art performance on various NLP tasks, including named entity recognition,

- sentiment analysis, and question answering. We previously leveraged this algorithm to
   identify patient gender identity in the EHR.<sup>7</sup>
- 225

## 226 Evaluation for Model Generalizability

To evaluate the generalizability of the models to the dataset regardless of keywords, we

applied the models trained in Dataset I to Dataset II. To evaluate the generalizability of

the models to the screening cohort, we applied the models trained in Datasets I and II to

230 Dataset III and reported the models' performance.

231

# 232 Comparison of machine learning-based models with rule-based approaches

The assess the feasibility of applying the deep learning model to identify AAV cases, we

compared its efficacy with that of two rule-based algorithms derived from administrative

claims data. Specifically, Rule 1 identifies patients who have any ICD-9 or ICD-10 codes

documented on at least two separated occasions. Rule 2 identifies patients with any

237 ICD-9 or ICD-10 codes recorded on at least two separated dates, and who also

received an AAV medication within a 6-month window (±6 months) of the first ICD code

recorded. For the deep learning model, we used the optimal model to analyze the

240 clinical notes of Cohort D. The highest section-level prediction probability was

considered as the patient-level model prediction probability. Patients with a predicted

probability of 1 were classified as positive for AAV.

243

After identifying potential AAV cases using either the rule-based or the deep learning model, we conducted a manual review of the EHR for these cases to pinpoint true

positive cases. From the cases not deemed to be AAV (i.e., those not identified by the
rules or the models), we randomly selected a subset (n=100) for manual chart review to
assess the false negative rate.

249

## 250 Statistical Analysis

We evaluated four statistical machine learning models, one deep learning model, and a 251 large language model for AAV case detection from clinical notes. Performance was 252 253 assessed based on the area under the receiver operating characteristic curve (AUROC), the area under the precision-recall curve (AUPRC), positive predictive value (PPV), 254 sensitivity, and F-1 score which accounts for both precision and recall by taking the 255 harmonic mean. Both the AUROC and AUPRC were computed using the scikit-learn 256 257 Python library (scikit-learn Developers). We estimated the 95% confidence intervals (CI) using 2,000 bootstrap iterations (Python, version 3.7; Python Software Foundation). To 258 compare the rule-based approaches with the top-performing AAV case identification 259 260 model, we computed the PPVs and sensitivities of all methods in Cohort D. Here the total number of true positive patients was determined by adding those identified by both 261 262 the rule-based approaches and the top-performing AAV case identification model.

263

#### 264 **RESULTS**

Cohort A, termed the 2002-2019 MGB AAV Cohort, included 700 PR3- or MPO-ANCA+
AAV patients. From these patients, 134,506 notes were extracted from the RPDR,
which included progress notes, ambulatory notes, and discharge summaries. These
notes were further split into 1,927,286 sections, of which 320,038 contained keywords.

269	Dataset I comprised 6,000 note sections, representing 5,765 notes from 1,638 patients
270	(968 [59.1%] female). Dataset II contained 3,008 sections from 2,970 notes,
271	representing 1,501 patients (885 [60.0%] female). Dataset III included 7,500 sections,
272	representing 5,429 notes from 1,000 patients (568 [56.8%] female) (Table 1). In Dataset
273	I, evidence of AAV was present in 2,669 sections (44.5%). Dataset II had 206 (6.8%)
274	sections positive for AAV. Out of the 3,008 sections in Dataset II, 457 contained at least
275	one keyword, with 203 (44.4%) of these containing evidence of AAV. Dataset III had 50
276	(0.67%) AAV-positive sections, and, of the 7,500 sections, 219 (2.92%) had one or
277	more keywords. Of those with keywords, 45 (20.5%) contained evidence of AAV.
278	
279	The performance of the five models in each dataset is outlined in Table 2. The
280	hierarchical attention-based deep learning model demonstrated the best performance
281	on Dataset I during cross-validation, significantly outperforming other models, with an
282	AUROC of 0.983 (95% CI, 0.980-0.986) and an AUPRC of 0.977 (95% CI, 0.972-
283	0.982). Compared to the deep learning model, Bio_ClinicalBERT had slightly worse
284	performance in AUROC and AUPRC in Dataset I; however, it achieved better results in
285	precision, recall, and F-1 score.
286	
287	Overall, all the models generalized well to Dataset II. The deep learning model exhibited

an AUROC of 0.991 (95% CI, 0.981-0.997) and an AUPRC of 0.962 (95% CI, 0.941-

- 0.980), with a 0.015 drop in AUPRC compared to its performance in Dataset I. Notably,
- in Dataset II and among all the models, the XGBoost model achieved the best

291	performance in AUPRC.	though the difference was	not statistically significant, and
231		anough the amonomou mae	not otation of and

Bio\_ClinicalBERT achieved the best sensitivity and F-1 score.

293

In Dataset III, the deep learning model outperformed other algorithms in all metrics.

295 Compared to its performance in Datasets I and II, it maintained a high AUROC of 0.991

296 (95% CI, 0.982-0.998); however, the AUPRC decreased to 0.760 (95% CI, 0.620-

297 0.885). Both Bio\_ClinicalBERT and XGBoost saw greater decrease in performance from

298 Datasets I and II to Dataset III.

299

Among 2,000 patients from the screening cohort, Rule 1 identified 218 with two or more

AAV-related ICD codes (Table 3). After excluding 12 patients due to insufficient

information to ascertain AAV status, 40 (19.4%) were confirmed to have AAV. Rule 2

identified 52 patients meeting Rule 1 criteria and receiving a medication prescription

within 6 months of the first ICD code; 11 (21.2%) had confirmed AAV. Among the 2,000

patients, 1,977 had clinical notes reviewed using the deep learning model, which

306 predicted AAV in 177 patients with a probability of 1. After excluding 5 patients due to

insufficient information, 45 (26.2%) patients were confirmed to have AAV.

308

A review of 100 randomly selected cases, which were not predicted as AAV by either method, confirmed the absence of AAV cases. If both the rules and the deep learning algorithms identified all positive AAV cases among the 2000 cases reviewed, the total number of positive cases amounted to 46. The estimated sensitivities for the deep learning model, Rule 1, and Rule 2 were 97.5%, 87.0%, and 23.9%, respectively.

2	1	Λ
J	т	4

315	Significant differences were observed when comparing patients identified by the deep
316	learning model versus rule-based algorithms (Table 3). The deep learning model
317	identified a more ethnically diverse group (Hispanic: 24% vs 2.5% and 0%, respectively)
318	and more ANCA-negative AAV cases. The deep learning model found six additional
319	patients not identified by Rule 1, accounting for 13.0% of the positive cases, and Rule 1
320	found one not identified by the deep learning model.
321	
322	Error Analysis
323	We analyzed the sections of clinical notes which the deep learning model falsely
324	predicted as consistent (false positive) with or not consistent (false negative) with AAV.
325	Many of the false positive errors can be grouped into three categories.
326	1. Ambiguous terms related to AAV. Some terms that appear in clinical notes
327	occasionally correspond to unrelated concepts with identical spelling. For example, the
328	abbreviation "MPA" might denote microscopic polyangiitis, which is pertinent to AAV, or
329	it could represent unrelated concepts like a multipurpose angiographic catheter or a
330	Master of Public Administration degree. Similarly, "GPA" can be used to abbreviate
331	grade point average.
332	2, Hypothetical scenarios in notes. Prediction errors also arose in note sections
333	described conjectural situations, such as guidelines of diagnosing AAV or potential
334	medication side effects (e.g., risks of anti-thyroid medications).

335	3. Notes detailing family history. The model made false positive predictions on notes
336	that mentioned a patient's family member being diagnosed with AAV, even though the
337	patient in question was not diagnosed.
338	
339	False negative errors can be attributed to various representation of AAV-related
340	keywords: 1. Dictation errors or misspellings. Some false negative cases contain typos
341	of AAV-related terms or instances of terms transcribed incorrectly (e.g., "Wagner's"
342	instead of "Wegener's").
343	2. Combined terms. Certain terms related to AAV were mentioned as part of large
344	tokens, which might not be recognized by the deep learning model. For instance,
345	"ANCA+MPO+vasculitis" or "GPA/Wegener's" were treated as distinct or unrelated
346	compared to simpler terms like "ANCA+" or "GPA" or "Wegener's".
347	3. Rare variations of AAV-related terms, such as, "WEgeners", "WEGENER'S" or
348	"GRANULOMATOSIS", which might not be well recognized by the deep learning model.
349	
350	When assessing model performance in 2,000 random patients from our screening
351	cohort, six patients were identified by the deep learning model but not by the rule-based
352	algorithm. After reviewing their charts, there are two potential reasons for these patients
353	were not captured by the rule-based algorithms. First, three patients were diagnosed
354	with AAV at institutions external to MGB so ICD codes for AAV were not used in
355	encounters in our healthcare system. Second, three patients had only one diagnosis
356	code, which did not meet the criteria of our rule-based algorithm. One patient identified
357	solely by the rule-based algorithm had positive ANCA pathology reports external to

MGB, which weren't included in the note screening. Available clinical notes lacked other specific features of AAV in this case.

360

#### 361 **DISCUSSION**

We found that a deep learning algorithm that integrated convolutional neural network, 362 recurrent neural network, and an attention mechanism trained using a small set of 363 keyword-identified, manually labeled note sections can be accurate and useful for 364 identifying a rare disease like AAV in a large cohort. The model performance in dataset I 365 366 showed its great capacity for detecting relevant signals from free-text narratives to make accurate predictions. The model was generalizable to notes, regardless of the presence 367 of keywords. When applied to notes of patients from a large screening cohort for AAV 368 369 case identification, the deep learning model out-performed the traditional rule-based algorithms which rely on ICD codes with or without medication prescriptions. 370

371

372 In addition to assessing the performance of the deep learning model, we also evaluated the performance of rule-based algorithms using ICD codes and medication prescriptions 373 374 in our healthcare system. This is the first study that incorporates ICD-10 codes into an 375 assessment of performance of this rule-based algorithm. We found that these rulebased algorithms had a PPV worse than that of the deep-learning model and that 376 377 incorporating medication prescriptions into the rule only slightly improved the PPV by 1.8%. In contrast, requiring a medication prescription significantly reduced sensitivity. 378 These observations speak to the need for innovative approaches, such as deep 379 380 learning, for developing new approaches for AAV case identification.

381

In comparing the deep learning approach with the ICD/medication-based rules, the 382 former demonstrated higher sensitivity and PPV. Examining clinical notes proved 383 beneficial in identifying additional cases, particularly those with a more remote history of 384 AAV or those diagnosed with AAV outside the MGB system. It also addressed cases 385 386 missed by the rule-based algorithm due to a limited number of ICD codes in the EHR. This will be helpful for identifying patients, for instance, who have severe disease and 387 die during their initial admission for AAV. This is particularly crucial in rare diseases, 388 where even a small increase in sample size and including patients with the most severe 389 spectrum of disease can significantly impact studies. While clinical notes revealed only 390 6 additional cases in a sample of 2,000, after extrapolating these observations to the 391 entire screening cohort (n=88,902) we suspect that the deep learning model could 392 identify approximately 7,868 patients, with an estimated 2,000 of them having AAV. 393 Compared with a rule-based algorithm approach, the deep learning algorithms could 394 395 identify an additional 267 patients while reducing the need for extensive chart reviews by more than 1,823 patients. 396

397

Compared with rule-based algorithms, we found that the deep learning model more often identified patients of Hispanic background and those with ANCA-negative disease. Why the deep learning model may have yielded a cohort with greater ethnic diversity is unclear. One possibility has to do with differences in the way that ICD codes are used for billing between people of different racial or ethnic backgrounds or because of the way patients of different racial or ethnic backgrounds interact with the healthcare

system. The ability of the deep learning model to identify a greater proportion of cases
with ANCA-negative granulomatosis with polyangiitis is another strength of this
approach. This population is often excluded from observational studies of AAV as well
as clinical trials and the ability to identify them easily will facilitate research of this
subgroup.

409

Our findings suggest that applying a deep learning model may have benefit regarding the efficiency of AAV cases identification. Rule-based approaches to AAV case finding which identify potential AAV cases through billing codes with or without medications typically necessitates a full chart review. In contrast, the deep learning model approach presents a significant advantage because once the model flags sections that are potentially related to AAV, only these specific sections typically require review,

416 potentially reducing the need for comprehensive chart evaluation.

417

Our study has several strengths. First, it was conducted in a large healthcare system
that includes both quaternary academic medical centers in addition to community
hospitals, primary care and specialty clinics, as well as specialty hospitals (e.g., ear,
nose throat hospital). Second, we applied four statistical machine learning models and
assessed their performance in comparison to commonly used rules-based algorithms.
Third, we assessed model performance using training and multiple validation datasets.

Despite these strengths, this study has certain limitations. First, we used data from a
 single healthcare system so the model was not evaluated for its generalizability using

427 data from other institutions. This is an important next step in the development of deep learning models to identify AAV cases. Second, the deep learning model was learned 428 from a small dataset, of which the vocabulary size might be relatively small. This might 429 430 affect the performance of the model when applied to a dataset with a larger vocabulary size. Third, the current approach leveraged only clinical notes to identify potential AAV 431 cases. It is possible that including other data sources for model learning, such as lab 432 results, may improve the performance of algorithms for identifying AAV cases. Fourth, 433 we noted a large decline in the PPV when we applied the deep learning model, which 434 435 was trained and assessed at the level of sections from notes, to classify at the patient level. This decrease can be attributed to the aggregation of errors from multiple note 436 sections per patient, which, when accumulated at the patient level, magnify the error 437 rate. 438

439

Our findings highlight the potential role of deep learning models for identifying positive 440 441 AAV cases from large screening cohorts. Moving forward, we intend to leverage our deep learning model to screen the entire cohort, anticipating the identification of over 442 443 2,000 AAV cases. A cohort of this size would be substantially larger than the current cohort assembled during a similar timeframe which includes fewer than 1,000 cases. 444 Thus, this represents a significant opportunity to expand the current MGB AAV cohort. 445 446 Furthermore, in the wake of the rise of sophisticated large language models, such as GPT-4, an intriguing avenue of research would be to compare the performance of our 447 448 deep learning model with these state-of-the-art language models. The evolution of

449	natural language processing tools offers promising opportunities to further enhance the
450	accuracy and efficiency of clinical data mining and disease identification.

## 451 CONCLUSION

- 452 This study is the first to show that a deep learning algorithm can efficiently and
- 453 accurately identify cases of AAV, a prototypic rare condition, in part by only using
- unstructured EHR data. This approach has the potential to identify cases that may be
- 455 overlooked if only using structured EHR data. This approach to case identification may
- improve the spectrum of disease captured for observational studies and reduce the time
- and resources often needed to review electronic health records. Future work will involve
- deploying the model to screen a broader cohort for potential AAV patients and
- 459 assessing performance in other healthcare systems.

## 460 **ACKNOWLEDGEMENTS**

462	References
463	1. Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-
464	associated vasculitis. Nature reviews Disease primers. 2020;6(1):71.
465	2. Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in
466	ANCA-associated vasculitis: ameta-analysis of observational studies. Annals of the
467	rheumatic diseases. 2017;76(9):1566-74.
468	3. Wang L, Miloslavsky E, Stone JH, Choi HK, Zhou L, Wallace ZS. Topic modeling
469	to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A
470	proof of concept study. Semin Arthritis Rheum. 2021;51(1):150-7. PMID: 33383291.
471	4. Wang L, Laurentiev J, Yang J, Lo YC, Amariglio RE, Blacker D, et al.
472	Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive
473	Decline From Clinical Notes in Electronic Health Records. JAMA Netw Open.
474	2021;4(11):e2135174. PMID: 34792589.
475	5. Yang J, Wang L, Phadke NA, Wickner PG, Mancini CM, Blumenthal KG, et al.
476	Development and Validation of a Deep Learning Model for Detection of Allergic
477	Reactions Using Safety Event Reports Across Hospitals. JAMA Netw Open.
478	2020;3(11):e2022836. PMID: 33196805.
479	6. Shao Y, Zeng QT, Chen KK, Shutes-David A, Thielke SM, Tsuang DW.
480	Detection of probable dementia cases in undiagnosed patients using structured and
481	unstructured electronic health records. BMC Med Inform Decis Mak. 2019;19(1):128.
482	PMID: 31288818.

483 7. Hua Y, Wang L, Nguyen V, Rieu-Werden M, McDowell A, Bates DW, et al. A deep learning approach for transgender and gender diverse patient identification in 484 electronic health records. J Biomed Inform. 2023;147:104507. PMID: 37778672. 485 8. Wallace ZS, Fu X, Cook C, Ahola C, Williams Z, Doliner B, et al. Comparative 486 Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction 487 Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of 488 Kidney Failure and Mortality. Arthritis Rheumatol. 2023;75(9):1599-607. PMID: 489 37011036. 490 Zhou L, Plasek JM, Mahoney LM, Karipineni N, Chang F, Yan X, et al. Using 491 9. Medical Text Extraction, Reasoning and Mapping System (MTERMS) to process 492 medication information in outpatient clinical notes. AMIA Annu Symp Proc. 493 494 2011;2011:1639-48. PMID: 22195230. 10. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. 495 Development and validation of a consensus methodology for the classification of the 496 497 ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-7. PMID: 16901958. 498 Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-499 11. associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. PMID: 32855422. 500 501 12. Chen T, Guestrin C, editors. Xgboost: A scalable tree boosting system. 502 Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining; 2016. 503 Zhang Y, Chen Q, Yang Z, Lin H, Lu Z. BioWordVec, improving biomedical word 504 13. 505 embeddings with subword information and MeSH. Scientific data. 2019;6(1):52.

- 506 14. Devlin J, Chang M-W, Lee K, Toutanova K. Bert: Pre-training of deep
- 507 bidirectional transformers for language understanding. arXiv preprint arXiv:181004805.
- 508 **2018**.
- 509
- 510

- 511 **Table 1**. Characteristics of the datasets I, II and III for the development and validation of models
- 512 for identifying evidence of ANCA vasculitis.

Characteristic	Dataset I	Dataset II	Dataset III
Sections, n	6,000	3,008	7,500
Notes, n	5,765	2,970	5,429
Character length per section, mean (SD)	839 (793)	443 (566)	410 (551)
Unique patients, n	1,638	1,501	1,000
Female, n (%)	968 (59.1)	885 (60.0)	568 (56.8)
Keyword present, n (%)	6,000 (100)	457 (15.2)	219 (2.9)
Sections consistent with a diagnosis of AAV, n (%)	2,669 (44.5)	206 (6.8)	50 (0.67)
Sections consistent with AAV diagnosis and containing a keyword of interest, n (%)	2,669 (44.5)	203 (44.4)	45 (20.5)

513 Abbreviations: AAV, ANCA-associated vasculitis; SD, standard deviation

Model	AUROC (95% CI)	AUPRC (95% CI)	PPV	Sensitivity	F-1 Score	
Dataset I (6,000 Note Sections)						
Logistic	0.923 (0.916-0.930)	0.892 (0.879-0.904)	0.857	0.777	0.815	
Regression						
Random Forest	0.929 (0.922-0.935)	0.888 (0.874-0.902)	0.808	0.886	0.845	
SVM	0.938 (0.932-0.944)	0.912 (0.901-0.923)	0.848	0.862	0.855	
XGBoost	0.957 (0.952-0.962)	0.939 (0.929-0.948)	0.916	0.896	0.906	
Bio_ClinicalBERT	0.957 (0.945-0.968)	0.962 (0.950- 0.972)	0.947	0.956	0.952	
Deep Learning	<b>0.983 (0.980-0.986</b> )	0.977 (0.972-0.982)	0.941	0.951	0.946	
	Datase	et II (3,008 Note Section	ons)		I	
Logistic	0.981 (0.969-0.991)	0.893 (0.858-0.925)	0.709	0.874	0.783	
Regression						
Random Forest	0.983 (0.976-0.989)	0.871 (0.832-0.904)	0.528	0.922	0.671	
SVM	0.983 (0.971-0.991)	0.910 (0.880-0.939)	0.645	0.908	0.754	
XGBoost	0.990 (0.981-0.997)	0.963 (0.941-0.981)	0.886	0.947	0.915	
Bio_ClinicalBERT	0.981 (0.967-0.992)	0.954 (0.933-0.973)	0.939	0.966	0.952	
Deep Learning	0.991 (0.981-0.997)	0.962 (0.941-0.980)	0.954	0.898	0.925	
	Datase	et III (7,500 Note Section	ons)			
Logistic	0.940 (0.906-0.967)	0.390 (0.259-0.534)	0.109	0.720	0.189	
Regression						
Random Forest	0.975 (0.962-0.986)	0.392 (0.258-0.529)	0.064	0.900	0.120	
SVM	0.907 (0.861-0.948)	0.402 (0.264-0.538)	0.080	0.700	0.143	
XGBoost	0.982 (0.955-0.996)	0.490 (0.359-0.633)	0.320	0.800	0.457	
Bio_ClinicalBERT	0.857 (0.792-0.917)	0.570 (0.473-0.659)	0.419	0.720	0.529	
Deep Learning	0.991 (0.982-0.998)	0.760 (0.620-0.885)	0.800	0.800	0.800	

## Table 2. Performance of four machine learning models for detecting AAV from clinical notes

515 Abbreviations: SVM, support vector machine; AUROC, area under the receiver operating

516 characteristic curve; AUPRC, the area under the precision-recall curve; PPV, positive predictive 517 value. Bold highlights the best performing model according to each measure.

518

519

521 **Table 3**. Characteristics of patients identified identified by the deep learning model and two rule-

	Deep Learning	Rule 1	Rule 2
Ν	177	218	52
AAV	45	40	11
Age at diagnosis, years	N = 43 (2 unknown)	N = 38 (2 unknown)	N = 11
Mean (SD)	54.79 (20.61)	55.97 (20.27)	56.64 (19.74)
Median (IQR)	60 (37 – 72)	60 (37.25 – 73.75)	60 (44.5 – 70.5)
<b>Sex</b> , female, n (%)	35 (77.78)	31 (77.50)	9 (81.82)
<b>Race</b> , n (%)			
White	38 (84.4)	33 (82.50)	10 (90.91)
Black	1 (2.2)	1 (2.50)	0
Asian	1 (2.2)	1 (2.50)	0
Other	1 (2.22%)	1 (2.50)	0
Unavailable	3 (6.67%)	3 (7.50)	0
Declined	1 (2.22%)	1 (2.50)	1 (9.09)
Ethnicity, n (%)			
Not Hispanic	33 (73.33%)	29 (72.5)	8 (72.73%)
Hispanic	11 (24.44%)	1 (2.5)	0
Unavailable	1 (2.22%)	10 (25.00%)	3 (27.27%)
ANCA Positive, n (%)	40 (88.89%)	37 (92.50%)	11 (100%)
	(1 unknown)		
<b>ANCA Type</b> , n (%)			
MPO	24 (53.33%)	23 (57.50%)	7 (63.64%)
PR3	14 (31.11%)	13 (32.50%)	3 (27.27%)
Neither	4 (8.89%)	3 (7.50%)	0
Unknown	3 (6.67%)	1 (2.50%)	1 (9.09%)

522 based algoirthms among 2,000 random sample of the screening cohort.

523 Abbreviation: AAV, ANCA-associated vasculitis; SD, standard deviation; IQR, Interquartile

<sup>524</sup> range; MPO, Myeloperoxidase; PR3, proteinase 3.

# 527 Figure Legends

528	Figure 1. Two-Phase Process for Identifying ANCA-Associated Vasculitis Cases. Phase
529	1 entails dataset creation along with the training and evaluation of models. Phase 2
530	compared the performance of the deep learning model with two rule-based algorithms.
531	
532	
533	Figure 2. Performance of the Machine Learning and Deep Learning Algorithms on
534	Datasets I, II, and III. A. Precision-recall curves for Dataset I. B. Receiver operating
535	characteristic (ROC) curves for Dataset I. C. Precision-recall curves for Dataset II. D.

536 ROC curves for Dataset II. E. Precision-recall curves for Dataset III. F. ROC curves for

537 Dataset III.

538

539



Phase I: Development and Validation of Deep Learning Models for Section Classification

Phase II: AAV Case Identification

